Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

Derivation of the sledai. A disease activity index for lupus patients

Claire Bombardier, Dafna D. Gladman, Murray B. Urowitz et al. · Arthritis & Rheumatism · 1992 · 4.5K citations

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis

Jonathan Edwards, L Szczepański, Jacek Szechiński et al. · New England Journal of Medicine · 2004 · 2.6K citations · Full text

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

Filip Baert, Maja Noman, Séverine Vermeire et al. · New England Journal of Medicine · 2003 · 2K citations · Full text

Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus

Matthew H. Liang, Steven A. Socher, Martin G. Larson et al. · Arthritis & Rheumatism · 1989 · 791 citations